Operating

Impairment Charges

AbbVie Impairment Charges remained flat by 0.0% to $211.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 95.3%, from $4.48B to $211.75M. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalLower is better
VolatilityVolatile
First reportedQ1 2015
Last reportedQ4 2025

How to read this metric

High impairment charges suggest poor capital allocation or a decline in the competitive value of the company's assets.

Detailed definition

Impairment charges are non-cash write-downs taken when the carrying value of an asset exceeds its fair market value. Thi...

Peer comparison

Common in industries with high intangible asset bases, such as pharma and consumer goods.

Metric ID: cf_impairment_charges

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$0.00$0.00$0.00$0.00$0.00$770.00M$0.00$710.00M$0.00$2.11B$1.41B$0.00$0.00$0.00$4.48B$211.75M$211.75M$211.75M$211.75M
QoQ Change-100.0%-100.0%-33.5%-100.0%-95.3%+0.0%+0.0%+0.0%
YoY Change+174.5%-100.0%-100.0%+218.6%-95.3%
Range$0.00$4.48B
Avg YoY Growth+19.6%
Median YoY Growth-95.3%
Current Streak3 quarters growth

Frequently Asked Questions

What is AbbVie's impairment charges?
AbbVie (ABBV) reported impairment charges of $211.75M in Q4 2025.
How has AbbVie's impairment charges changed year-over-year?
AbbVie's impairment charges decreased by 95.3% year-over-year, from $4.48B to $211.75M.
What does impairment charges mean?
A non-cash charge taken when an asset is determined to be worth less than its recorded value.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.